Results 11 to 20 of about 636,170 (221)
The Development of BTK Inhibitors: A Five-Year Update
Molecules, 2021 Bruton’s tyrosine kinase (BTK) represented, in the past ten years, an important target for the development of new therapeutic agents that could be useful for cancer and autoimmune disorders.
Bruno Tasso +3 more
doaj +2 more sources
Comparison of inhibitory effects of irreversible and reversible Btk inhibitors on platelet function
eJHaem, 2021 All irreversible Bruton tyrosine kinase (Btk) inhibitors including ibrutinib and acalabrutinib induce platelet dysfunction and increased bleeding risk. New reversible Btk inhibitors were developed, like MK‐1026.
Bibian M.E. Tullemans +13 more
doaj +2 more sources
Evolution of BTK inhibitors [PDF]
Lynchburg Journal of Medical ScienceThe purpose of this clinical review evaluates the evolution of bruton’s tyrosine kinase (BTK) inhibitors in becoming the standard of care in treating chronic lymphocytic leukemia (CLL). The first-generation BTK inhibitor ibrutinib has demonstrated superior efficacy over traditional chemotherapy in several randomized clinical trials in terms of ...
Mathew, Dena
openaire +2 more sources
Targeting Solid Tumors With BTK Inhibitors [PDF]
Frontiers in Cell and Developmental Biology, 2021 The repurposing of FDA-approved Bruton’s tyrosine kinase (BTK) inhibitors as therapeutic agents for solid tumors may offer renewed hope for chemotherapy-resistant cancer patients.
Fatih M. Uckun, Taracad Venkatachalam
doaj +3 more sources
BTK Inhibitors for the Treatment of Mantle Cell Lymphoma-Current Status and Perspectives. [PDF]
Cancers (Basel)The introduction of Bruton’s tyrosine kinase inhibitors (BTKis) has significantly improved prognosis in the treatment of MCL. BTK inhibitors have demonstrated strong activity in the treatment of relapsed/refractory patients with mantle cell lymphoma (MCL)
Robak T, Wolska-Washer A, Robak P.
europepmc +2 more sources
Bruton tyrosine kinase inhibitors as potential therapeutic agents for COVID-19: A review
Metabolism Open, 2021 Coronavirus disease 2019 (COVID-19) is first detected in December 2019 in Wuhan, China which is a new pandemic caused by SARS-COV-2 that has greatly affected the whole world.
Zemene Demelash Kifle
doaj +1 more source
BTK Inhibitors Impair Platelet-Mediated Antifungal Activity [PDF]
, 2022 In recent years, the introduction of new drugs targeting Bruton’s tyrosine kinase (BTK) has allowed dramatic improvement in the prognosis of patients with chronic lymphocytic leukemia (CLL) and other B-cell neoplasms. Although these small molecules
Roberto Marasca +19 more
core +2 more sources
Current Oncology, 2023 The most common forms of B-cell malignancy, non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL), have seen a drastic shift in the treatment landscape over the last two decades with the introduction of targeted agents.
Shannon Nixon +3 more
doaj +1 more source
Phylogeny of Tec Family Kinases: Identification of a Pre-Metazoan Origin of Btk, Bmx, Itk, Tec, Txk and the Btk Regulator SH3BP5 [PDF]
, 2008 It is generally considered mammals and birds have five Tec family kinases (TFKs): Btk, Bmx (also known as Etk), Itk, Tec, and Txk (also known as Rlk). Here, we discuss the domains and their functions and regulation in TFKs.
Ortutay, Csaba +3 more
core +2 more sources
Differential impact of BTK active site inhibitors on the conformational state of full-length BTK
eLife, 2020 Bruton’s tyrosine kinase (BTK) is targeted in the treatment of B-cell disorders including leukemias and lymphomas. Currently approved BTK inhibitors, including Ibrutinib, a first-in-class covalent inhibitor of BTK, bind directly to the kinase active site.
Raji E Joseph +5 more
doaj +1 more source